Real-World Healthcare Resource Utilization (HRU) and Costs of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Receiving Eculizumab in a US Population.
Wendy Y ChengSujata P SardaNikita Mody-PatelSangeeta KrishnanMihran YenikomshianMalena MahendranDominique LejeuneLouise H YuMei Sheng DuhPublished in: Advances in therapy (2021)
The economic burden of patients with PNH treated with eculizumab is greater among those dependent on blood transfusions.